TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio is headquartered in South San Francisco, California.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $85M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | SV Health ... | svhealthin... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.03.2022 | Series A | $26M | - |
| 22.06.2021 | Series A | $59M | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.06.2024 | TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases | SOUTH SAN FRANCISCO, June 26, 2024 – TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that collaboration partner Eli Lilly and Company (“Lilly”) h... |
| 08.03.2022 | TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases | SOUTH SAN FRANCISCO, Calif., March 8, 2022 — TRexBio Inc., a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, today announced it has completed a $26 million extension of its Series A financi... |
| 08.03.2022 | TRexBio Closes $26M Series A Extension Funding | TrexBio, a South San Francisco, CA-based discovery stage biotech company, raised $26M in Series A extension funding. The round, which brings the total Series A funding raised to $85m, was led by Polaris Partners and Laurion Capital, with pa... |
| 22.06.2021 | TRexBio : Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases | TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59 million Series A financing. Proceeds from the financing will be used ... |
| 22.06.2021 | TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases | June 22, 2021 08:00 AM Eastern Daylight Time |